Scarica l'app Stockscreener
28.76
0.93%
-0.27
Dopo l'orario di chiusura:
28.76
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché RARE Giù?
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$29.03
Aprire:
$28.58
Volume 24 ore:
2.04M
Relative Volume:
1.10
Capitalizzazione di mercato:
$2.83B
Reddito:
$669.43M
Utile/perdita netta:
$-609.36M
Rapporto P/E:
-4.71
EPS:
-6.1061
Flusso di cassa netto:
$-507.20M
1 W Prestazione:
+15.73%
1M Prestazione:
+22.96%
6M Prestazione:
-15.73%
1 anno Prestazione:
-21.91%
Intervallo 1D:
$28.50
$29.39
Intervallo di 1 settimana:
$25.09
$29.39
Portata 52W:
$18.29
$42.37
Ultragenyx Pharmaceutical Inc Stock (RARE) Company Profile
Nome
Ultragenyx Pharmaceutical Inc
Settore
Industria
Telefono
415-483-8800
Indirizzo
60 LEVERONI COURT, NOVATO, CA
Compare RARE vs VRTX, REGN, ARGX, ALNY, RVMD
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
RARE
Ultragenyx Pharmaceutical Inc
|
28.76 | 2.70B | 669.43M | -609.36M | -507.20M | -6.1061 |
VRTX
Vertex Pharmaceuticals Inc
|
468.42 | 114.63B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
618.03 | 63.95B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
853.40 | 54.58B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
288.18 | 37.13B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
169.51 | 34.65B | 742.00K | -1.37B | -1.07B | -7.0731 |
Ultragenyx Pharmaceutical Inc Stock (RARE) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-03-24 | Downgrade | Goldman | Buy → Neutral |
| 2025-10-20 | Iniziato | Wells Fargo | Overweight |
| 2025-07-28 | Ripresa | H.C. Wainwright | Buy |
| 2025-05-28 | Iniziato | William Blair | Outperform |
| 2024-06-06 | Aggiornamento | Goldman | Neutral → Buy |
| 2024-04-22 | Iniziato | RBC Capital Mkts | Outperform |
| 2023-12-08 | Iniziato | Wells Fargo | Overweight |
| 2023-06-14 | Ripresa | Credit Suisse | Outperform |
| 2023-06-06 | Aggiornamento | Evercore ISI | In-line → Outperform |
| 2023-04-26 | Iniziato | Cantor Fitzgerald | Overweight |
| 2023-01-18 | Ripresa | Canaccord Genuity | Buy |
| 2022-12-30 | Ripresa | H.C. Wainwright | Buy |
| 2022-11-03 | Aggiornamento | Robert W. Baird | Neutral → Outperform |
| 2022-10-13 | Aggiornamento | Guggenheim | Neutral → Buy |
| 2022-08-01 | Downgrade | Evercore ISI | Outperform → In-line |
| 2022-03-16 | Aggiornamento | Credit Suisse | Neutral → Outperform |
| 2022-02-11 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2021-09-30 | Iniziato | H.C. Wainwright | Buy |
| 2021-08-19 | Iniziato | UBS | Sell |
| 2021-07-15 | Iniziato | Guggenheim | Neutral |
| 2021-06-29 | Aggiornamento | BofA Securities | Neutral → Buy |
| 2021-06-04 | Ripresa | Robert W. Baird | Neutral |
| 2021-05-06 | Aggiornamento | Citigroup | Neutral → Buy |
| 2021-05-06 | Aggiornamento | Evercore ISI | In-line → Outperform |
| 2021-04-26 | Ripresa | Credit Suisse | Neutral |
| 2021-03-02 | Ripresa | Stifel | Buy |
| 2021-02-12 | Downgrade | JP Morgan | Overweight → Neutral |
| 2020-12-07 | Downgrade | Wedbush | Outperform → Neutral |
| 2020-11-24 | Ripresa | Evercore ISI | In-line |
| 2020-11-12 | Downgrade | BofA Securities | Buy → Neutral |
| 2019-08-02 | Ripresa | Wedbush | Outperform |
| 2019-03-27 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2019-02-22 | Ripresa | Raymond James | Outperform |
| 2019-01-02 | Downgrade | Raymond James | Outperform → Mkt Perform |
| 2018-11-08 | Aggiornamento | Citigroup | Sell → Neutral |
| 2018-09-10 | Iniziato | Morgan Stanley | Equal-Weight |
| 2018-06-21 | Downgrade | Credit Suisse | Outperform → Neutral |
| 2018-05-11 | Aggiornamento | Barclays | Equal Weight → Overweight |
| 2018-05-10 | Iniziato | Goldman | Neutral |
| 2018-04-18 | Aggiornamento | SunTrust | Hold → Buy |
| 2018-03-22 | Ripresa | Piper Jaffray | Overweight |
| 2018-02-21 | Reiterato | Stifel | Buy |
| 2018-01-22 | Aggiornamento | Evercore ISI | In-line → Outperform |
| 2018-01-18 | Iniziato | Credit Suisse | Outperform |
| 2017-12-05 | Reiterato | Barclays | Equal Weight |
| 2017-12-04 | Aggiornamento | Jefferies | Hold → Buy |
| 2017-09-14 | Aggiornamento | Wedbush | Neutral → Outperform |
Mostra tutto
Ultragenyx Pharmaceutical Inc Borsa (RARE) Ultime notizie
Ultragenyx: The Setrusumab Reset Creates A Cleaner Rare Disease Opportunity - Seeking Alpha
RARE Stock Slumps On Multiple Wall Street Price Target Slashes, Clinical Pipeline Uncertainty - Stocktwits
Ultragenyx grants 44,409 restricted stock units to 15 new non-executive officers as an inducement. - Pluang
Ultragenyx awards 44,409 RSUs to 15 new hires - Stock Titan
RARE Stock Edges Up On Priority Review For Gene Therapy In Rare Metabolic Disorder - Stocktwits
Ultragenyx Pharmaceutical Inc (RARE) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Ultragenyx Pharmaceutical Inc - TradingKey
Ultragenyx Pharmaceutical Inc (RARE) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Ultragenyx Pharmaceutical Inc (RARE) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Ultragenyx Pharmaceutical Inc (RARE) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Ultragenyx Pharmaceutical Inc (RARE) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Ultragenyx Pharmaceutical Inc (RARE) Valuation: PE, PB & Fair Value Analysis - TradingKey
Ultragenyx Pharmaceutical Inc (RARE) Institutional Confidence - TradingKey
Why (RARE) Price Action Is Critical for Tactical Trading - Stock Traders Daily
Ultragenyx (RARE) Is Up 17.6% After ESOP Share Shelf And Conference Spotlight On Gene Therapies – Has The Bull Case Changed? - simplywall.st
Ultragenyx Pharmaceutical Inc (RARE) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Insider Sell Alert: Sanders Corazon (Corsee) D. Sells Shares of Ultragenyx Pharmaceutical Inc (RARE) - GuruFocus
Ultragenyx EVP sells $46,753 in common stock By Investing.com - Investing.com Australia
Ultragenyx director Corazon D. Sanders sells $50,100 in stock - Investing.com
Ultragenyx EVP sells $46,753 in common stock - Investing.com
Ultragenyx director Corazon D. Sanders sells $50,100 in stock By Investing.com - Investing.com Canada
Ultragenyx (RARE) director sells 2,000 shares at $25.05 - Stock Titan
Ultragenyx (RARE) legal chief sells 1,899 company shares in open market - Stock Titan
[144] Ultragenyx Pharmaceutical Inc. SEC Filing - Stock Titan
RARE (NASDAQ) proposed sale of 2,000 restricted shares by broker-dealer - Stock Titan
Ultragenyx Pharmaceutical (RARE) Gains 1.5% as Stock Tests Key Resistance Near $25.57Stop Hunt - newsline.com
Here is Why Ultragenyx Pharmaceutical (RARE) is One of the Best Buy-the-Dip Stocks - Insider Monkey
Ultragenyx Pharmaceutical Inc. $RARE Stock Holdings Lifted by GW&K Investment Management LLC - MarketBeat
Motley Fool Wealth Management LLC Lowers Position in Ultragenyx Pharmaceutical Inc. $RARE - MarketBeat
Los Angeles Capital Management LLC Sells 60,515 Shares of Ultragenyx Pharmaceutical Inc. $RARE - MarketBeat
RARE: Transformative year ahead with pivotal data, gene therapy launches, and path to profitability - TradingView
RARE: Phase III Angelman data and gene therapy launches set the stage for profitability by 2027 - TradingView
How The Ultragenyx Pharmaceutical (RARE) Investment Story Is Shifting With New Data And Street Views - Yahoo Finance
Ultragenyx Pharmaceutical Inc. $RARE Shares Acquired by BNP Paribas Financial Markets - MarketBeat
Ultragenyx Pharmaceutical (NASDAQ:RARE) Stock Rating Upgraded by Wall Street Zen - MarketBeat
Institutional Confidence in GTX-102 Fuels Optimism for Ultragenyx Pharmaceutical (RARE) - Insider Monkey
Ultragenyx EVP and chief medical officer Crombez sells $8,586 in shares - Investing.com Nigeria
Kuehn Law Encourages Investors of Ultragenyx Pharmaceutical Inc. to Contact Law Firm - Morningstar
Ultragenyx (RARE) Down 13.6% Since Last Earnings Report: Can It Rebound? - Yahoo Finance
Ultragenyx to Participate at Goldman Sachs 47th Annual Global Healthcare Conference - The Manila Times
What to Know About This Fund's $5.4 Million Ultragenyx Purchase as Shares Slip 30% in One Year - AOL.com
Insider Sell: Howard Horn Sells Shares of Ultragenyx Pharmaceuti - GuruFocus
Ultragenyx CFO Horn sells $110,601 in company stock By Investing.com - Investing.com Australia
Insider Selling: Ultragenyx Pharmaceutical (NASDAQ:RARE) CFO Sells 4,653 Shares of Stock - MarketBeat
Ultragenyx CFO Horn sells $110,601 in company stock - Investing.com
Ultragenyx Pharmaceutical (RARE) CFO sells 4,653 common shares - Stock Titan
Ultragenyx (RARE) Pushes Higher on Positive Clinical Momentum – Key Levels to WatchNarrow Range Breakout - newsline.com
Ultragenyx Pharmaceutical Inc Azioni (RARE) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.48%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):